Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Parsons, Henrique A ^a   Baracos, Vickie E ^b   Dhillon, Navjot ^a   Hong, David S ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AMNESIA; ANOREXIA; ANTHROPOMETRY; BODY COMPOSITION; BODY MASS; CANCER CENTER; CANCER PATIENT; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DISTRESS SYNDROME; DROWSINESS; DYSPNEA; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; NAUSEA; OBESITY; OVERALL SURVIVAL; PAIN; PARESTHESIA; PATIENT ASSESSMENT; PATIENT CODING; PATIENT REFERRAL; PREDICTION; REVIEW; SYMPTOM; VOMITING; XEROSTOMIA; ARTICLE; CANCER STAGING; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); STATISTICS; SURVIVAL;

BODY COMPOSITION; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS; REFERRAL AND CONSULTATION; SURVIVAL ANALYSIS;

EID: 84855318187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029330     Document Type: Review

References (53)

1. Murthy NS, Mukherjee S, Ray G, Ray A, (2009) Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J Postgrad Med 55: 45-54.
2. Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, et al. (2003) Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 11: 652-659.
3. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, et al. (2008) Cachexia: a new definition. Clin Nutr 27: 793-799.
4. Ma G, Alexander HR, (1998) Prevalence and pathophysiology of cancer cachexia. In: Bruera E, Portenoy R, editors. Topics in Palliative Care New York Oxford University Press pp. 91-129.
5. Deans DA, Wigmore SJ, de Beaux AC, Paterson-Brown S, Garden OJ, et al. (2007) Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br J Surg 94: 1501-1508.
6. Fearon KC, Voss AC, Hustead DS, (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83: 1345-1350.
7. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69: 491-497.
8. Fouladiun M, Korner U, Gunnebo L, Sixt-Ammilon P, Bosaeus I, et al. (2007) Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res 13: 6379-6385.
9. Hinsley R, Hughes R, (2007) 'The reflections you get': an exploration of body image and cachexia. Int J Palliat Nurs 13: 84-89.
10. Dahele M, Skipworth RJ, Wall L, Voss A, Preston T, et al. (2007) Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage 33: 676-685.
11. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS, (2001) Sarcopenia. J Lab Clin Med 137: 231-243.
12. Roubenoff R, (2008) Excess baggage: sarcopenia, obesity, and cancer outcomes. Lancet Oncol 9: 605-607.
13. Roubenoff R, (2002) Exercise, sarcopenia, cognition, and mood. Nestle Nutr Workshop Ser Clin Perform Programme 6: 151-159; discussion 160-152.
14. Roubenoff R, (2003) Sarcopenia: effects on body composition and function. J Gerontol A Biol Sci Med Sci 58: 1012-1017.
15. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, et al. (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15: 2920-2926.
16. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, et al. (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9: 629-635.
17. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC, (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15: 6973-6979.
18. Bouchard DR, Dionne IJ, Brochu M, (2009) Sarcopenic/obesity and physical capacity in older men and women: data from the Nutrition as a Determinant of Successful Aging (NuAge)-the Quebec longitudinal Study. Obesity (Silver Spring) 17: 2082-2088.
19. Rolland Y, Lauwers-Cances V, Cristini C, Abellan van Kan G, Janssen I, et al. (2009) Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study. Am J Clin Nutr 89: 1895-1900.
20. Argiles JM, Busquets S, Lopez-Soriano FJ, (2006) Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res 130: 199-217.
21. Argiles JM, Busquets S, Lopez-Soriano FJ, (2003) Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 6: 401-406.
22. Argiles JM, Garcia-Martinez C, Llovera M, Lopez-Soriano FJ, (1992) The role of cytokines in muscle wasting: its relation with cancer cachexia. Med Res Rev 12: 637-652.
23. Jensen GL, (2008) Inflammation: roles in aging and sarcopenia. JPEN J Parenter Enteral Nutr 32: 656-659.
24. Saini A, Al-Shanti N, Stewart CE, (2006) Waste management- cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 17: 475-486.
25. Myers JS, (2008) Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 35: 802-807.
26. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, et al. (2008) Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 9: 777-785.
27. Seruga B, Zhang H, Bernstein LJ, Tannock IF, (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8: 887-899.
28. Wood LJ, Nail LM, Gilster A, Winters KA, Elsea CR, (2006) Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 33: 535-542.
29. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, et al. (2009) Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer 115: 1091-1099.
30. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, et al. (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89: 1634-1646.
31. Quinn J, Kramer N, McDermott D, (2008) Validation of the Social Security Death Index (SSDI): An Important Readily-Available Outcomes Database for Researchers. West J Emerg Med 9: 6-8.
32. Social Security Death Index Access Webpage through http://www.genealogybank.com/gbnk/ssdi/. Accessed March 2010.
33. Billewicz WZ, Kemsley WF, Thomson AM, (1962) Indices of adiposity. Br J Prev Soc Med 16: 183-188.
34. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, et al. (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33: 997-1006.
35. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, et al. (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97: 2333-2338.
36. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, et al. (2004) Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr 80: 271-278.
37. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, et al. (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85: 115-122.
38. Heymsfield SB, Smith R, Aulet M, Bensen B, Lichtman S, et al. (1990) Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr 52: 214-218.
39. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, et al. (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351: 871-875.
40. Kurzrock R, Benjamin RS, (2005) Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 352: 930-932.
41. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, et al. (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352: 895-904.
42. Finlay E, Lu HL, Henderson H, O'Dwyer PJ, Casarett DJ, (2009) Do phase 1 patients have greater needs for palliative care compared with other cancer patients? Cancer 115: 446-453.
43. Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, et al. (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19: 787-792.
44. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, et al. (2009) Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27: 2692-2696.
45. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, et al. (2011) Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer In press.
46. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, et al. (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 28: 1054-1060.
47. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, et al. (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147: 755-763.
48. Kamel HK, (2003) Sarcopenia and aging. Nutr Rev 61: 157-167.
49. Evans W, (1997) Functional and metabolic consequences of sarcopenia. J Nutr 127: 998S-1003S.
50. Shaffer JR, Kammerer CM, Reich D, McDonald G, Patterson N, et al. (2007) Genetic markers for ancestry are correlated with body composition traits in older African Americans. Osteoporos Int 18: 733-741.
51. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, et al. (2007) Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 120: 863-870.
52. Kalantar-Zadeh K, Kopple JD, (2006) Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 151: 57-69.
53. Schmidt D, Salahudeen A, (2007) The obesity-survival paradox in hemodialysis patients: why do overweight hemodialysis patients live longer? Nutr Clin Pract 22: 11-15.